What's Happening?
Bristol Myers Squibb (BMS) is significantly expanding its neuroscience pipeline, building on its 2019 merger with Celgene. The company is developing a range of therapies for neurological and neuropsychiatric diseases, including Alzheimer's disease and multiple
sclerosis (MS). Key initiatives include the evaluation of Cobenfy for Alzheimer's disease psychosis, bipolar-1 mania, Alzheimer's cognition, and pediatric autism irritability. BMS is also progressing with a dual FAAH/MAGL inhibitor, irafamdastat, in Phase 2 trials for MS spasticity and agitation associated with Alzheimer's, and the anti-MTBR-tau antibody moponetug in Phase 2 development as a disease-modifying therapy for Alzheimer's. Ken Rhodes, vice president of neuroscience at BMS, highlighted the company's re-entry into the neuroscience space, emphasizing the value derived from Celgene's portfolio. The company is also exploring brain shuttle technologies to deliver therapeutic modalities across the blood-brain barrier, exemplified by a global license agreement with BioArctic for its BrainTransporter technology to target Alzheimer's.
Why It's Important?
This strategic expansion by BMS is crucial for addressing the growing global burden of neurological and neuropsychiatric disorders, particularly Alzheimer's disease, which is the most common form of dementia. The development of both disease-modifying therapies and treatments for debilitating symptoms reflects a comprehensive approach to patient care. The focus on brain shuttle technologies could revolutionize drug delivery to the central nervous system, potentially enabling the targeting of previously 'undruggable' targets and offering more convenient administration routes. This could lead to significant advancements in treating complex brain disorders, improving patient outcomes, and potentially reducing healthcare costs associated with long-term care for these conditions. The re-engagement of major pharmaceutical companies like BMS in neuroscience, driven by advancements in biomarkers and genetics, signals a renewed hope for breakthroughs in a field that has historically seen high clinical trial failure rates.
What's Next?
BMS anticipates readouts for Cobenfy in Alzheimer's disease psychosis in 2027, with a possible interim analysis later this year, which will be a significant milestone for the company's neuroscience portfolio. The ongoing Phase 2 trials for irafamdastat and moponetug will provide further data on their efficacy and safety. BMS also plans to continue its discovery and early development work on brain shuttle technologies, with undisclosed earlier-stage programs incorporating various shuttle technologies. The company's strategy involves replicating its 'continuum of care' approach, which combines disease-modifying therapies with symptomatic treatments, across other disease areas. Future business development efforts may also focus on expanding core therapeutic areas like neuroscience. The broader neuroscience field will likely see continued investment in biomarkers and genetics to improve the probability of success in clinical trials, especially for psychiatric diseases where understanding of causal biology is less mature.
Beyond the Headlines
The renewed interest and investment by major pharmaceutical companies in neuroscience, particularly in Alzheimer's disease, signifies a potential paradigm shift in how these complex conditions are approached. The emphasis on a 'continuum of care' strategy, addressing both disease modification and symptom management, acknowledges the multifaceted nature of neurological disorders and the diverse needs of patients. The exploration of advanced drug delivery mechanisms, such as brain shuttle technologies, highlights a deeper understanding of the biological barriers to effective treatment and a commitment to overcoming them. This could lead to not only more effective treatments but also less invasive and more patient-friendly administration methods. Furthermore, the lessons learned from advancements in Alzheimer's research, particularly in genetics and biomarkers, are expected to inform and accelerate progress in other neuropsychiatric diseases, potentially leading to a broader 'neuroscience renaissance' across the industry.
